Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis.
Alemtuzumab
CMV
Multiple sclerosis
Opportunistic infections
Journal
Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
02
08
2018
revised:
21
09
2018
accepted:
30
09
2018
pubmed:
14
10
2018
medline:
18
4
2019
entrez:
14
10
2018
Statut:
ppublish
Résumé
Alemtuzumab (a drug highly active in multiple sclerosis) is a humanized monoclonal antibody targeting the surface molecule CD52. It causes a rapid depletion of innate and adaptive immune cells with a peak during the first month after infusion. Infection rates in alemtuzumab-treated patients with multiple sclerosis in clinical trials were higher in than in interferon beta-treated patients. Cytomegalovirus (CMV) primary infections and reactivations have been reported in this setting of patients. We describe the case of a patient that developed both viral (CMV) and bacterial pneumonia one month after alemtuzumab infusion for multiple sclerosis. Physicians dealing with this drug should be aware of this serious but treatable complication.
Identifiants
pubmed: 30316174
pii: S2211-0348(18)30357-2
doi: 10.1016/j.msard.2018.09.031
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Alemtuzumab
3A189DH42V
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
44-45Informations de copyright
Copyright © 2018. Published by Elsevier B.V.